Shareholders of India’s Gland Pharma, an injectables manufacturer, are said to be considering selling a 74% stake to China’s Fosun Pharma as a hedge against…

Trump wants to lower the tax burden for companies bringing cash back to the U.S. from overseas, but repatriation may not spur M&A.

Swiss CDMO Lonza forecast in its half-year earnings report it will produce about $7.9 billion in annual revenues by 2022, strengthened by the recent purchase…

Australia’s TPI Enterprises has struck a deal to buy the opioid and CMO tablet businesses of Norway’s Vistin Pharma.

AGC Asahi Glass, which bought CMC Biologics this year, will make its Seattle, Washington, area operation the headquarters of its drug business.

CDMO Patheon is investing $45 million in four sites that stretch from the West Coast of the U.S. to Italy.

Particle Sciences will have commercial manufacturing capabilities operating at its Pennsylvania facility by the end of the year and will add 30 jobs.

Japan’s Sawai is following other drugmakers by establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.

Thermo Fisher Scientific is acquiring Patheon—the center of the consolidation that has swept through contract manufacturing—in a deal valued at $7.2 billion.

The Teva divestment rumors are true. The company wants to sell off its women’s health and European oncology and pain businesses to pay down debt.

M&A